Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    BioNexus Gene Lab Corp.

    NASDAQ: BGLC · Real-Time Price · USD
    2.77
    -0.15 (-4.97%)
    At close: Jun 13, 2025, 3:59 PM
    2.76
    -0.28%
    After-hours: Jun 13, 2025, 04:00 PM EDT

    BioNexus Gene Lab Statistics

    Share Statistics

    BioNexus Gene Lab has 1.8M shares outstanding. The number of shares has increased by 1.7% in one year.

    Shares Outstanding

    n/a
    		 1.8M

    Shares Change (YoY)

    n/a
    		 1.7%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 1.17M

    Failed to Deliver (FTD) Shares

    n/a
    		 4,475

    FTD / Avg. Volume

    n/a
    		 0.68%

    Short Selling Information

    The latest short interest is 61.65K, so 3.43% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 61.65K

    Short % of Shares Out

    n/a
    		 3.43%

    Short % of Float

    n/a
    		 3.43%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -31.21 and the forward PE ratio is null. BioNexus Gene Lab's PEG ratio is 0.66.

    PE Ratio

    n/a
    		 -31.21

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 5.25

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 5.99

    P/FCF Ratio

    n/a
    		 -20.27

    PEG Ratio

    n/a
    		 0.66
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for BioNexus Gene Lab.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.03.

    Current Ratio

    n/a
    		 3.81

    Quick Ratio

    n/a
    		 3.1

    Debt / Equity

    n/a
    		 0.03

    Debt / EBITDA

    n/a
    		 -0.15

    Debt / FCF

    n/a
    		 -0.09

    Interest Coverage

    n/a
    		 -74.42

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $317,021.53

    Profits Per Employee

    n/a
    		 $-53,278.07

    Employee Count

    n/a
    		 30

    Asset Turnover

    n/a
    		 0.91

    Inventory Turnover

    n/a
    		 5.92

    Taxes

    Income Tax

    n/a
    		 3.49K

    Effective Tax Rate

    n/a
    		 -0.22%

    Stock Price Statistics

    The stock price has increased by -38.83% in the last 52 weeks. The beta is 1.91, so BioNexus Gene Lab's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.91

    52-Week Price Change

    n/a
    		 -38.83%

    50-Day Moving Average

    n/a
    		 2.9

    200-Day Moving Average

    n/a
    		 3.37

    Relative Strength Index (RSI)

    n/a
    		 46.1

    Average Volume (20 Days)

    n/a
    		 657,444

    Income Statement

    In the last 12 months, BioNexus Gene Lab had revenue of 9.51M and earned -1.6M in profits. Earnings per share was -0.09.

    Revenue

    n/a
    		 9.51M

    Gross Profit

    n/a
    		 1.29M

    Operating Income

    n/a
    		 -1.57M

    Net Income

    n/a
    		 -1.6M

    EBITDA

    n/a
    		 -1.42M

    EBIT

    n/a
    		 -1.57M

    Earnings Per Share (EPS)

    n/a
    		 -0.09
    Full Income Statement

    Balance Sheet

    The company has 4.38M in cash and 210.56K in debt, giving a net cash position of 4.17M.

    Cash & Cash Equivalents

    n/a
    		 4.38M

    Total Debt

    n/a
    		 210.56K

    Net Cash

    n/a
    		 4.17M

    Retained Earnings

    n/a
    		 -3.44M

    Total Assets

    n/a
    		 9.48M

    Working Capital

    n/a
    		 4.98M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -2.23M and capital expenditures -226.99K, giving a free cash flow of -2.46M.

    Operating Cash Flow

    n/a
    		 -2.23M

    Capital Expenditures

    n/a
    		 -226.99K

    Free Cash Flow

    n/a
    		 -2.46M

    FCF Per Share

    n/a
    		 -0.14
    Full Cash Flow Statement

    Margins

    Gross margin is 13.56%, with operating and profit margins of -16.55% and -16.81%.

    Gross Margin

    n/a
    		 13.56%

    Operating Margin

    n/a
    		 -16.55%

    Pretax Margin

    n/a
    		 -16.77%

    Profit Margin

    n/a
    		 -16.81%

    EBITDA Margin

    n/a
    		 -14.94%

    EBIT Margin

    n/a
    		 -16.55%

    FCF Margin

    n/a
    		 -25.88%

    Dividends & Yields

    BGLC does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for BGLC.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Apr 7, 2025. It was a backward split with a ratio of 1:10.

    Last Split Date

    n/a
    		 Apr 7, 2025

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:10

    Scores

    Altman Z-Score

    n/a
    		 2.86

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist